|
Female/male
|
16 (46%)/19 (54%)
|
23 (44%)/29 (56%)
|
0.53
|
|
Age (years)
|
36 (23–54)
|
42 (28–50)
|
0.42
|
|
Disease duration (years)
|
4.0 (1.0–9.2)
|
2.7 (1.1–7.0)
|
0.75
|
|
Disease type: extensive/left-sided
|
31 (89%)/4 (11%)
|
40 (77%)/12 (23%)
|
0.14
|
|
Body mass index
|
19.4 (16.4–22.5)
|
19.6 (17.0–22.2)
|
0.77
|
|
Lichtiger index
|
13 (12–14)
|
13 (12–15)
|
0.81
|
|
Endoscopic score (UCEIS)
|
6 (5–7)
|
6 (4–8)
|
0.03
|
|
Hemoglobin (g/dL)
|
10.3 (10.0–12.7)
|
11.8 (9.5–13.1)
|
0.44
|
|
Albumin (g/dL)
|
3.2 (2.7–3.7)
|
3.3 (2.6–3.7)
|
0.85
|
|
C-reactive protein (mg/dL)
|
3.8 (0.9–10.2)
|
3.1 (1.6–7.6)
|
0.96
|
|
Erythrocyte sedimentation rate (mm/h)
|
48 (30–83)
|
54 (33–75)
|
0.93
|
|
Creatinine (mg/dL)
|
0.7 (0.6–0.8)
|
0.7 (0.6–0.8)
|
0.92
|
|
Corticosteroid refractory/dependent
|
23 (66%)/12 (34%)
|
43 (83%)/9 (17%)
|
0.06
|
|
Biologic agent naive
|
28 (80%)
|
33 (64%)
|
0.08
|
|
Intravenous tacrolimus
|
30 (86%)
|
35 (67%)
|
0.04
|
|
Decrease of Lichtiger index ≥ 3 points by day 3
|
21 (60%)
|
11 (21%)
|
< 0.01
|
|
response at 1 week (LI decrease by 3 and less than 10)
|
32 (91%)
|
18 (35%)
|
< 0.01
|
|
Tacrolimus concentration ≥ 10 ng/ml at day 1
|
21 (60%)
|
26 (50%)
|
0.24
|
|
Tacrolimus concentration ≥ 10 ng/ml at day 3
|
31 (89%)
|
42 (81%)
|
0.25
|
|
Adverse events
|
10 (29%)
|
8 (15%)
|
0.11
|
